Synergistic activity of an RNA polymerase PA-PB1 interaction inhibitor with oseltamivir against human and avian influenza viruses in cell culture and in ovo.

• Published in: Antiviral Research
• Main Authors: Bonomini, Anna, Zhang, Jiwei, Ju, Han, Zago, Alessia, Pacetti, Martina, Tabarrini, Oriana, Massari, Serena, Liu, Xinyong, Mercorelli, Beatrice, Zhan, Peng, Loregian, Arianna
• Format: Article in Journal/Newspaper
• Language: English
• Published: Elsevier Science 2024
• Subjects: Avian flu; Combination therapy; Embryonated chicken egg model; Influenza viruses; Neuraminidase inhibitors; Protein-protein interaction inhibitor
• Online Access: https://doi.org/10.1016/j.antiviral.2024.105980; https://pubmed.ncbi.nlm.nih.gov/39117284

In search of novel therapeutic options to treat influenza virus (IV) infections, we previously identified a series of inhibitors that act by disrupting the interactions between the PA and PB1 subunits of the viral RNA polymerase. These compounds showed broad-spectrum antiviral activity against human influenza A and B viruses and a high barrier to the induction of drug resistance in vitro. In this short communication, we investigated the effects of combinations of the PA-PB1 interaction inhibitor 54 with oseltamivir carboxylate (OSC), zanamivir (ZA), favipiravir (FPV), and baloxavir marboxil (BXM) on the inhibition of influenza A and B virus replication in vitro. We observed a synergistic effect of the 54/OSC and 54/ZA combinations and an antagonistic effect when 54 was combined with either FPV or BXM. Moreover, we demonstrated the efficacy of 54 against highly pathogenic avian influenza viruses (HPAIVs) both in cell culture and in the embryonated chicken eggs model. Finally, we observed that 54 enhances OSC protective effect against HPAIV replication in the embryonated eggs model. Our findings represent an advance in the development of alternative therapeutic strategies against both human and avian IV infections.